|
|
 |
|
Viewing report
|
|
|
|
California Cancer Consortium - Developmental Therapeutics Review - Q4 2010
Global Markets Direct, Dec 2010, Pages: 77
California Cancer Consortium – Developmental Therapeutics Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “California Cancer Consortium – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by California Cancer Consortium.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of California Cancer Consortium with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of California Cancer Consortium’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in California Cancer Consortium’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate California Cancer Consortium’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of California Cancer Consortium in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with California Cancer Consortium.
- Avoid Intellectual Property Rights related issues.
|
|
|
|
